Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

27.8%

10 terminated/withdrawn out of 36 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

39%

14 trials in Phase 3/4

Results Transparency

108%

27 of 25 completed trials have results

Key Signals

27 with results5 withdrawn

Enrollment Performance

Analytics

Phase 4

11(34.4%)

Phase 2

8(25.0%)

Phase 1

6(18.8%)

Phase 3

3(9.4%)

Early Phase 1

2(6.3%)

N/A

2(6.3%)

32Total

Phase 4(11)

Phase 2(8)

Phase 1(6)

Phase 3(3)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials

NCT01668030Phase 4Completed

Comparison of Wound Bed Establishment in Facial Burns

Role: collaborator

NCT00900029Completed

Safety Follow-Up to HP 802-247-09-015

Role: lead

NCT01737762Phase 3Completed

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

Role: lead

NCT01190865Phase 1Completed

Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds

Role: lead

NCT01359735Phase 2Completed

Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients

Role: lead

NCT01970657Completed

Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247

Role: lead

NCT00852995Phase 2Completed

Dose Finding Study of HP802-247 in Venous Leg Ulcers

Role: lead

NCT01853384Phase 3Terminated

Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Role: lead

NCT02154087Phase 2Terminated

A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

Role: lead

NCT01656889Phase 3Completed

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

Role: lead

NCT02111291Phase 4Completed

Santyl Applications to Diabetic Foot Ulcers

Role: lead

NCT01253135Phase 1Completed

Study to Determine if Fibrin Affects the Ability of a Wound to Heal

Role: lead

NCT01835379Phase 4Completed

Study of Oasis Ultra in Diabetic Foot Ulcers

Role: lead

NCT01408277Phase 4Completed

Using Santyl on Diabetic Foot Ulcers

Role: lead

NCT01208220Not ApplicableTerminated

Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers

Role: collaborator

NCT00767676Phase 1Completed

Contact Sensitization Potential of 828 Ointment

Role: lead

NCT00767455Phase 1Completed

Cumulative Irritation Potential of 828 Ointment

Role: lead

NCT01433159Phase 2Terminated

Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury

Role: lead

NCT01658618Unknown

Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer

Role: lead

NCT00971048Not ApplicableCompleted

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

Role: lead